<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.3"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Sci Rep</journal-id><journal-id journal-id-type="iso-abbrev">Sci Rep</journal-id><journal-title-group><journal-title>Scientific Reports</journal-title></journal-title-group><issn pub-type="epub">2045-2322</issn><publisher><publisher-name>Nature Publishing Group UK</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">40404729</article-id><article-id pub-id-type="pmc">PMC12098999</article-id>
<article-id pub-id-type="publisher-id">2109</article-id><article-id pub-id-type="doi">10.1038/s41598-025-02109-5</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Associations between urinary glycosaminoglycans and onset of acute respiratory distress syndrome in sepsis patients: a prospective exploratory study</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes"><name><surname>Shen</surname><given-names>Ziyuan</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Li</surname><given-names>Zhengying</given-names></name><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Zhang</surname><given-names>Hua</given-names></name><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Wei</surname><given-names>Xiaoyun</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Wei</surname><given-names>Senhao</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Zhao</surname><given-names>Feng</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Yang</surname><given-names>Cui</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Cong</surname><given-names>Zhukai</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Yin</surname><given-names>Zhongnan</given-names></name><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Ding</surname><given-names>Chenchen</given-names></name><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Tie</surname><given-names>Cai</given-names></name><address><email>tiecai@cumtb.edu.cn</email></address><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Zhu</surname><given-names>Xi</given-names></name><address><email>xizhuccm@bjmu.edu.cn</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/04wwqze12</institution-id><institution-id institution-id-type="GRID">grid.411642.4</institution-id><institution-id institution-id-type="ISNI">0000 0004 0605 3760</institution-id><institution>Department of Critical Care Medicine, </institution><institution>Peking University Third Hospital, </institution></institution-wrap>Beijing, 100191 China </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/01xt2dr21</institution-id><institution-id institution-id-type="GRID">grid.411510.0</institution-id><institution-id institution-id-type="ISNI">0000 0000 9030 231X</institution-id><institution>School of Chemical and Environmental Engineering, </institution><institution>China University of Mining and Technology-Beijing, </institution></institution-wrap>Beijing, 100083 China </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/01xt2dr21</institution-id><institution-id institution-id-type="GRID">grid.411510.0</institution-id><institution-id institution-id-type="ISNI">0000 0000 9030 231X</institution-id><institution>State key laboratory Coal resources and Safe Mining, </institution><institution>China University of Mining and Technology-Beijing, </institution></institution-wrap>Beijing, 100083 China </aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/04wwqze12</institution-id><institution-id institution-id-type="GRID">grid.411642.4</institution-id><institution-id institution-id-type="ISNI">0000 0004 0605 3760</institution-id><institution>Center of Epidemiology, </institution><institution>Peking University Third Hospital, </institution></institution-wrap>Beijing, 100191 China </aff><aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/04wwqze12</institution-id><institution-id institution-id-type="GRID">grid.411642.4</institution-id><institution-id institution-id-type="ISNI">0000 0004 0605 3760</institution-id><institution>Biobank, </institution><institution>Peking University Third Hospital, </institution></institution-wrap>Beijing, 100191 China </aff></contrib-group><pub-date pub-type="epub"><day>22</day><month>5</month><year>2025</year></pub-date><pub-date pub-type="pmc-release"><day>22</day><month>5</month><year>2025</year></pub-date><pub-date pub-type="collection"><year>2025</year></pub-date><volume>15</volume><elocation-id>17783</elocation-id><history><date date-type="received"><day>19</day><month>10</month><year>2024</year></date><date date-type="accepted"><day>12</day><month>5</month><year>2025</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2025</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article&#x02019;s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article&#x02019;s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>.</license-p></license></permissions><abstract id="Abs1"><p id="Par1">The aim of the current study was to explore the association between urinary glycosaminoglycans and the onset of acute respiratory distress syndrome (ARDS) in sepsis patients. We conducted a prospective cohort study of 49 sepsis patients and collected clinical characteristics, urine, and blood samples within 24&#x000a0;h of admission to the Surgical Intensive Care Unit (SICU) of Peking University Third Hospital. Samples from patients who did not develop ARDS were collected from day 1 to day 7 after SICU admission, while samples from patients who developed ARDS were collected from day 1 to the day of onset, forming time-series data. A liquid chromatography-mass spectrometry (LC-MS) system was used to determine urinary dermatan sulfate (DS), chondroitin sulfate (CS), and heparan sulfate (HS) concentrations; enzyme-linked immunosorbent assay (ELISA) and cytometric bead array (CBA) were used to measure plasma inflammatory factors. The endpoint was the onset of ARDS. We used generalized estimating equations to identify associations between urinary glycosaminoglycans and ARDS onset in sepsis patients. Twenty-two of the 49 sepsis patients developed ARDS, and 132 plasma samples and 132 urine samples were obtained. Between the ARDS and non-ARDS groups, sex, pneumonia, Acute Physiology and Chronic Health Evaluation II (APACHE II), Lung Injury Prediction Score (LIPS), and PaO<sub>2</sub>/FiO<sub>2</sub> showed statistically significant differences. Generalized estimating equations showed that DS and tumor necrosis factor-&#x003b1; (TNF-&#x003b1;) were independently associated with ARDS onset in sepsis patients, but their generalizability across ARDS subtypes warrants further validation.</p><sec><title>Supplementary Information</title><p>The online version contains supplementary material available at 10.1038/s41598-025-02109-5.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Glycosaminoglycans</kwd><kwd>Inflammatory factors</kwd><kwd>Sepsis</kwd><kwd>Acute respiratory distress syndrome</kwd><kwd>Risk factors</kwd></kwd-group><kwd-group kwd-group-type="npg-subject"><title>Subject terms</title><kwd>Predictive markers</kwd><kwd>Respiratory distress syndrome</kwd></kwd-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100010270</institution-id><institution>Capital Health Research and Development of Special Fund</institution></institution-wrap></funding-source><award-id>2020-2-4094</award-id><award-id>2020-2-4094</award-id><award-id>2020-2-4094</award-id><award-id>2020-2-4094</award-id><award-id>2020-2-4094</award-id><award-id>2020-2-4094</award-id><award-id>2020-2-4094</award-id><principal-award-recipient><name><surname>Shen</surname><given-names>Ziyuan</given-names></name><name><surname>Wei</surname><given-names>Xiaoyun</given-names></name><name><surname>Wei</surname><given-names>Senhao</given-names></name><name><surname>Zhao</surname><given-names>Feng</given-names></name><name><surname>Yang</surname><given-names>Cui</given-names></name><name><surname>Cong</surname><given-names>Zhukai</given-names></name><name><surname>Zhu</surname><given-names>Xi</given-names></name></principal-award-recipient></award-group></funding-group><funding-group><award-group><funding-source><institution>Peking University Third Hospital Cohort Study Project</institution></funding-source><award-id>BYSYDL2021010</award-id><award-id>BYSYDL2021010</award-id><award-id>BYSYDL2021010</award-id><award-id>BYSYDL2021010</award-id><award-id>BYSYDL2021010</award-id><award-id>BYSYDL2021010</award-id><award-id>BYSYDL2021010</award-id><principal-award-recipient><name><surname>Shen</surname><given-names>Ziyuan</given-names></name><name><surname>Wei</surname><given-names>Xiaoyun</given-names></name><name><surname>Wei</surname><given-names>Senhao</given-names></name><name><surname>Zhao</surname><given-names>Feng</given-names></name><name><surname>Yang</surname><given-names>Cui</given-names></name><name><surname>Cong</surname><given-names>Zhukai</given-names></name><name><surname>Zhu</surname><given-names>Xi</given-names></name></principal-award-recipient></award-group></funding-group><funding-group><award-group><funding-source><institution>Beijing Municipal Natural Science Foundation</institution></funding-source><award-id>7212130</award-id><award-id>7212130</award-id><award-id>7212130</award-id><award-id>7212130</award-id><award-id>7212130</award-id><award-id>7212130</award-id><award-id>7212130</award-id><principal-award-recipient><name><surname>Shen</surname><given-names>Ziyuan</given-names></name><name><surname>Wei</surname><given-names>Xiaoyun</given-names></name><name><surname>Wei</surname><given-names>Senhao</given-names></name><name><surname>Zhao</surname><given-names>Feng</given-names></name><name><surname>Yang</surname><given-names>Cui</given-names></name><name><surname>Cong</surname><given-names>Zhukai</given-names></name><name><surname>Zhu</surname><given-names>Xi</given-names></name></principal-award-recipient></award-group></funding-group><funding-group><award-group><funding-source><institution>National Natural Science Foundation of China</institution></funding-source><award-id>82172166</award-id><award-id>82172166</award-id><award-id>82172166</award-id><award-id>82172166</award-id><award-id>82172166</award-id><award-id>82172166</award-id><award-id>82172166</award-id><principal-award-recipient><name><surname>Shen</surname><given-names>Ziyuan</given-names></name><name><surname>Wei</surname><given-names>Xiaoyun</given-names></name><name><surname>Wei</surname><given-names>Senhao</given-names></name><name><surname>Zhao</surname><given-names>Feng</given-names></name><name><surname>Yang</surname><given-names>Cui</given-names></name><name><surname>Cong</surname><given-names>Zhukai</given-names></name><name><surname>Zhu</surname><given-names>Xi</given-names></name></principal-award-recipient></award-group></funding-group><funding-group><award-group><funding-source><institution>Key Clinical Projects of Peking University Third Hospital</institution></funding-source><award-id>BYSYZD2023012</award-id><award-id>BYSYZD2023012</award-id><award-id>BYSYZD2023012</award-id><award-id>BYSYZD2023012</award-id><award-id>BYSYZD2023012</award-id><award-id>BYSYZD2023012</award-id><award-id>BYSYZD2023012</award-id><principal-award-recipient><name><surname>Shen</surname><given-names>Ziyuan</given-names></name><name><surname>Wei</surname><given-names>Xiaoyun</given-names></name><name><surname>Wei</surname><given-names>Senhao</given-names></name><name><surname>Zhao</surname><given-names>Feng</given-names></name><name><surname>Yang</surname><given-names>Cui</given-names></name><name><surname>Cong</surname><given-names>Zhukai</given-names></name><name><surname>Zhu</surname><given-names>Xi</given-names></name></principal-award-recipient></award-group></funding-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; Springer Nature Limited 2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Introduction</title><p id="Par38">Sepsis is defined as the host&#x02019;s uncontrolled response to infection leading to organ dysfunction that endangers the patient&#x02019;s life<sup><xref ref-type="bibr" rid="CR1">1</xref></sup>, which is a common cause of acute respiratory distress syndrome (ARDS). The heterogeneity of ARDS, lack of specific diagnostic criteria and therapies, and rapid progression after diagnosis lead to high mortality ranging from 35&#x02013;46%<sup><xref ref-type="bibr" rid="CR2">2</xref></sup>. Currently, cytokine storm is considered an important pathophysiological mechanism for ARDS development, and thus increasing numbers of studies are attempting to use clinical parameters and blood inflammatory factors to predict or diagnose ARDS. In addition, there is an urgent need to discover new biomarkers that are more representative and predictive in value.</p><p id="Par39">Disruption of the glycocalyx in the development of ARDS is also receiving increasing attention. The glycocalyx is a gel-like layer covering the luminal surface of endothelial cells<sup><xref ref-type="bibr" rid="CR3">3</xref></sup>, which is composed of proteoglycans, glycosaminoglycans (GAGs), and glycoproteins. It also adheres circulating proteins like albumin to form the endothelial surface<sup><xref ref-type="bibr" rid="CR4">4</xref></sup>. A large number of basic and clinical studies have demonstrated that the glycocalyx plays important roles in maintaining vascular permeability, sensing fluid shear forces<sup><xref ref-type="bibr" rid="CR5">5</xref></sup>, preventing microthrombosis<sup><xref ref-type="bibr" rid="CR6">6</xref></sup> and regulating leukocyte adhesion<sup><xref ref-type="bibr" rid="CR7">7</xref></sup>. The glycocalyx is modulated by endothelial stabilizing agents, physical forces on the vascular wall, and inflammatory factors<sup><xref ref-type="bibr" rid="CR8">8</xref></sup>. In addition, the glycocalyx is also found to cover epithelium. Researchers have found that alveolar epithelial glycocalyx degradation disrupts surfactant function<sup><xref ref-type="bibr" rid="CR9">9</xref></sup>. Changes in vascular permeability caused by degradation of the glycocalyx in alveolar capillary endothelium lead to bilateral pulmonary edema, ultimately resulting in ARDS.</p><p id="Par40">GAGs are important components of the glycocalyx, which consist of repeating disaccharide units and are covalently attached to proteins to form proteoglycans. According to the different disaccharide units, GAGs are divided into chondroitin/dermatan sulfate (CS/DS), heparin/heparan sulfate (Hep/HS), keratan sulfate (KS), and non-sulfated hyaluronan (HA). Except for KS, which consists of hexosamine and galactose, others are all composed of hexosamine and hexuronic acid. Besides, the number and position of the sulfate residues, and the presence of N-acetyl and/or N-sulfate groups contribute to the diversity of GAGs<sup><xref ref-type="bibr" rid="CR10">10</xref></sup>. According to Rizzo&#x02019;s research, in ARDS, airspace fluid GAGs concentrations correlate with lung injury severity and disease course<sup><xref ref-type="bibr" rid="CR9">9</xref></sup>. Queisser found that in COVID-19, fragments of GAGs were released into the blood circulation, which could further aggravate the disease<sup><xref ref-type="bibr" rid="CR11">11</xref></sup>. Carmichael showed that elevations in circulating GAGs were positively correlated with postoperative Sequential Organ Failure Assessment (SOFA) scores at 24&#x000a0;h in intra-abdominal sepsis patients<sup><xref ref-type="bibr" rid="CR12">12</xref></sup>. Circulating GAGs are filtered by the nephrons and excreted in the urine (showed in Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>). Schmidt confirmed that urinary GAGs had predictive value for disease progression in sepsis and ARDS patients<sup><xref ref-type="bibr" rid="CR13">13</xref></sup>. However, no studies have yet demonstrated whether there is a correlation between urinary GAGs and the occurrence of ARDS. Therefore, in this study, we aim to investigate whether urinary GAGs are associated with the subsequent occurrence of ARDS by measuring urinary GAGs levels in septic patients and tracking whether they develop ARDS and the time of onset, which may lay a foundation for identifying novel biomarkers for predicting ARDS.</p><p id="Par41">
<fig id="Fig1"><label>Fig. 1</label><caption><p>Endothelial GAG shedding disrupts the alveolar-capillary barrier, causing pulmonary edema, with shed GAGs excreted in urine.This map was generated by NIAID Visual &#x00026; Medical Arts. (2024/10/8). Alveoli. NIAID NIH BIOART Source. bioart.niaid.nih.gov/bioart/14; NIAID Visual &#x00026; Medical Arts. (2024/10/8). Blood Vessel. NIAID NIH BIOART Source. bioart.niaid.nih.gov/bioart/55; Human Reference Atlas. (2024/12/19). Renal Corpuscle. NIAID NIH BIOART Source. bioart.niaid.nih.gov/bioart/562.</p></caption><graphic xlink:href="41598_2025_2109_Fig1_HTML" id="d33e623"/></fig>
</p></sec><sec id="Sec2"><title>Methods</title><p id="Par42">The study was reviewed and approved by the Institutional Review Board of Peking University Third Hospital (Beijing, China) (ethics number M2020278) and was performed in accordance with relevant guidelines and regulations. Written informed consent was obtained from each patient or their relative.</p><sec id="Sec021"><title>Study population</title><p id="Par44">The study was performed in a 20-bed surgical intensive care unit (SICU) of Peking University Third Hospital (Beijing, China) between January 2022 and December 2022. The study design, performance, and report complied with the Standards for Reporting of Diagnostic Accuracy guidelines<sup><xref ref-type="bibr" rid="CR14">14</xref></sup>. Sepsis patients enrolled in our study comprised two categories: (1) patients who developed secondary sepsis following surgery (e.g., intra-abdominal infections after gastrointestinal surgery); (2) patients with primary sepsis who have undergone surgical intervention (e.g., suppurative cholangitis, intestinal perforation).They were monitored and treated following international guidelines for management of sepsis and septic shock<sup><xref ref-type="bibr" rid="CR15">15</xref></sup>.</p><p id="Par45">The patients with sepsis who stayed in the SICU longer than 48&#x000a0;h were prospectively and consecutively enrolled. The exclusion criteria included: (1) patients without consent; (2) age&#x02009;&#x0003c;&#x02009;18 years; (3) chronic kidney disease; (4) organ or bone marrow transplantation; (5) receiving mannitol or heparin treatment; (6) developed ARDS before admission; and (7) more than 30% missing data.</p></sec><sec id="Sec002"><title>Sample collection</title><p id="Par47">Blood and urine were collected within 24&#x000a0;h of admission to the SICU. Samples from patients who did not develop ARDS were collected from day 1 to day 7 after SICU admission, while samples from patients with ARDS were collected from day 1 to the day of onset. Days of sample collection are shown in Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>.</p><p id="Par48">
<fig id="Fig2"><label>Fig. 2</label><caption><p>Days of sample collection in sepsis patients. Patients didn&#x02019;t develop ARDS: Day1-Day7; Patients developed ARDS: Day1-The day of onset.</p></caption><graphic xlink:href="41598_2025_2109_Fig2_HTML" id="d33e658"/></fig>
</p></sec><sec id="Sec30"><title>Materials</title><p id="Par50">MS-grade water, acetonitrile, Acetic acid, methanol (Fisher Scientific, USA).DS, CS and HS standards (Sigma-Aldrich, USA), CBA kits (Biolegend, China), ELISA kits (Abebio, China).</p></sec><sec id="Sec3"><title>Bio-markers measurements</title><sec id="Sec300"><title>Urinary GAGs testing: pretreatment of bio-samples</title><p id="Par52">500&#x000a0;&#x000b5;l of urine samples were centrifuged at 15,000/g for 5&#x000a0;min,15&#x000a0;&#x000b5;l supernatant was transferred to a Polymerase Chain Reaction(PCR) tubes and dried with vacuum concentrator. 100&#x000a0;&#x000b5;l of 1.25&#x000a0;mol/l methanol hydrochloride was added into each tube, incubation was carried out at 65 &#x000b0;C for 5&#x000a0;h.The reaction solvent was concentrate dried with vacuum concentrator. The dried samples were stored at &#x02013; 20 &#x000b0;C, prior to Ultra High-Performance Liquid Chromatography - Multiple Reaction Monitoring (UHPLC-MRM) analysis. The dried samples were reconditioned with 100&#x000a0;&#x000b5;l acetonitrile/water (90/10,v/v) and injected directly.</p></sec><sec id="Sec4"><title>Urinary GaGs testing: UHPLC-MRM analysis</title><p id="Par53">DS, CS and HS analysis were performed on the LC-MS system consisting of a SCIEX Triple Quad 5500&#x02009;+&#x02009;MS with an ESI source (MA, USA) and a Thermo Scientific Dionex Ultimate 3000 HPLC (MA, USA). A Waters ACQUITY UPLC BEH amide (2.1&#x02009;&#x000d7;&#x02009;75&#x000a0;mm) was adapted. Mobile phase A was 10 mM acetic acid aqueous solution, and mobile phase B was acetonitrile. Elution conditions are shown in Supplementary Table <xref rid="MOESM1" ref-type="media">1</xref>. The flow rate was 0.3&#x000a0;ml/min. The column temperature was set as 30&#x000a0;&#x000b0;C. The injection volume was 5&#x000a0;&#x000b5;l. Data acquisition was performed with positive-mode.</p></sec></sec><sec id="Sec5"><title>Plasma inflammatory factors testing</title><p id="Par54">Acquired blood samples were rested for 30&#x000a0;min and subsequently centrifuged at 2500&#x000a0;rpm at 4 &#x000b0;C for 10&#x000a0;min, and supernatant plasma was stored and frozen at &#x02013; 80 &#x000b0;C until used. Plasma concentrations of Interferon-&#x003b3; (IFN-&#x003b3;),Tumor necrosis factor-&#x003b1; (TNF-&#x003b1;), Monocyte chemoattractant protein-1 (MCP-1), Interleukin-6 (IL-6), Interleukin-8 (IL-8),Interleukin-10 (IL-10) were measured by commercial CBA kits (Biolegend, China), and we used ELISA kits (Abebio, China) to measure Angiopoietin II (Ang II), Krebs von den Lungen-6 (KL-6), Receptor for advanced glycation end products (RAGE), following the manufacturer&#x02019;s protocol.</p><p id="Par55">The biomarkers were measured by technicians of the Biobank of Peking University Third Hospital who were blinded to clinical data, and the physicians in charge were blinded to the biomarker test results.</p></sec><sec id="Sec6"><title>Clinical endpoints and definition</title><p id="Par56">All patients with sepsis were diagnosed by Sepsis-3 criteria in 2016<sup><xref ref-type="bibr" rid="CR1">1</xref></sup>, and ARDS was diagnosed according to the Berlin Definition in 2012<sup><xref ref-type="bibr" rid="CR16">16</xref></sup>. The primary endpoint was the onset of ARDS within 7 days after enrollment.</p><p id="Par57">The primary endpoint was determined by two experienced clinicians who were blinded to the expression of the urinary GAGs or plasma inflammatory factors. If there was any objection, a third clinician was invited to assist in the diagnosis. If still not certain, the diagnosis was made again 4&#x02013;6&#x000a0;h later until the diagnosis was clear or excluded.</p></sec><sec id="Sec7"><title>Clinical data extraction</title><p id="Par58">All clinical data were prospectively collected on the basis of case report forms (CRF).The baseline characteristics, clinical/laboratory parameters were collected within 24&#x000a0;h of admission into the SICU from the electronic medical record system, including age, sex, Body Mass Index(BMI), patients sources, comorbidities, infection site, laboratory test results, methods of respiratory support, use of vasopressors or Continuous Renal Replacement Therapy (CRRT).Clinical scores included Lung injury prediction score (LIPS), Physiology and Chronic Health Evaluation II (APACHE II) and Sequential Organ Failure Assessment (SOFA).</p></sec><sec id="Sec8"><title>Statistical analysis</title><p id="Par59">The data acquisition was carried out with Analyst 1.7.1 (ABsciex, MA, USA). Version 1.6 OS-Q (ABsciex, MA, USA) was employed for peak integration and quantification. IBM SPSS 27 (Armonk, New York, USA), R 4.3.0, and EZinfo (Waters, MA, USA) were employed for statistical analysis. Continuous variables were presented as mean&#x02009;&#x000b1;&#x02009;standard deviation (SD) or median with quartiles 1 and 3 (Q1&#x02013;Q3), and categorical variables were presented as percentiles. Continuous data between groups were compared using the t-test or Mann&#x02013;Whitney U test, and categorical variables were compared using the chi-square test. For all analyses, statistical significance was indicated by a two-sided <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05. We used multivariable generalized estimating equations with an independent correlation structure to estimate the association between urinary GAGs and the onset of ARDS, after accounting for the severity of the patients&#x02019; diseases and the levels of inflammatory factors in plasma. Correlated data were analyzed using Spearman correlation. The open-source tool MetaboAnalyst 5.0 (HYPERLINK: <ext-link ext-link-type="uri" xlink:href="http://www.metaboanalyst.ca/">http://www.metaboanalyst.ca/</ext-link>) was also employed for statistical analysis and graph drawing.</p></sec></sec><sec id="Sec9"><title>Results</title><p id="Par60">During the study period, 165 patients who were admitted to the SICU of Peking University Third Hospital were screened. Among them, 4 patients stayed in the SICU for less than 3 days, 3 patients were aged&#x02009;&#x0003c;&#x02009;18 years old, and 80 patients did not have sepsis. After excluding other ineligible patients, 49 patients were finally enrolled and were divided into 22 patients with ARDS and 27 patients with non-ARDS based on daily tracking of the patients&#x02019; conditions. Figure&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref> shows the process of cohort selection.</p><p id="Par61">
<fig id="Fig3"><label>Fig. 3</label><caption><p>Flow chart of the study selection.22 patients with ARDS and 27 patients with non-ARDS were obtained.</p></caption><graphic xlink:href="41598_2025_2109_Fig3_HTML" id="d33e727"/></fig>
</p><sec id="Sec125"><title>Baseline characteristics and clinical/laboratory parameters</title><p id="Par63">In our cohort, there were 22 sepsis patients who developed ARDS. The comparison results showed that on the first day of admission, there were no significant differences between ARDS and non-ARDS patients in age, BMI, patient sources, hypertension, coronary heart disease, diabetes, malignant tumor, urinary tract infection, peritonitis, SOFA score, methods of respiratory support, use of vasopressors/CRRT, serum creatinine, or estimated glomerular filtration rate (eGFR). However, compared with non-ARDS patients, sex, pneumonia, APACHEII score, LIPS score, and PaO<sub>2</sub>/FiO<sub>2</sub> showed statistical differences. As expected, sepsis patients with ARDS had a higher 28-day mortality after admission to the SICU: mortality rates were 6 (27.27%) vs. 1 (3.70%), <italic>p</italic>&#x02009;=&#x02009;0.023, respectively. The baseline characteristics and clinical/laboratory parameters are shown in Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>.</p><p id="Par64">
<table-wrap id="Tab1"><label>Table 1</label><caption><p>Baseline characteristics and clinical/laboratory parameters.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Variable</th><th align="left">ARDS(<italic>n</italic>&#x02009;=&#x02009;22)</th><th align="left">Non-ARDS(<italic>n</italic>&#x02009;=&#x02009;27)</th><th align="left"><italic>P</italic> value</th></tr></thead><tbody><tr><td align="left"><p>Age (year)</p><p>(Q1-Q3)</p></td><td align="left">71.50 (64.00, 76.50)</td><td align="left">64.00 (42.00, 76.00)</td><td char="." align="char">0.124</td></tr><tr><td align="left">Sex (male) (%)</td><td align="left">17 (77.27%)</td><td align="left">11 (40.74)</td><td char="." align="char">0.019*</td></tr><tr><td align="left">BMI (Q1-Q3)</td><td align="left">24.05 (22.04, 25.64)</td><td align="left">23.20 (21.30, 26 0.10)</td><td char="." align="char">0.666</td></tr><tr><td align="left" colspan="4">Patients source</td></tr><tr><td align="left">&#x000a0;Other department (%)</td><td align="left">7 (31.82%)</td><td align="left">5 (18.52%)</td><td char="." align="char">0.282</td></tr><tr><td align="left"><p>&#x000a0;Emergency department</p><p>and postoperation (%)</p></td><td align="left">14 (63.64%)</td><td align="left">19 (70.37%)</td><td char="." align="char">0.617</td></tr><tr><td align="left">&#x000a0;Elective postoperation (%)</td><td align="left">1 (4.55%)</td><td align="left">3 (11.11%)</td><td char="." align="char">0.404</td></tr><tr><td align="left" colspan="4">Comorbidity</td></tr><tr><td align="left">&#x000a0;Hypertension (%)</td><td align="left">12 (54.55%)</td><td align="left">10 (37.04%)</td><td char="." align="char">0.220</td></tr><tr><td align="left"><p>&#x000a0;Coronary heart</p><p>disease (%)</p></td><td align="left">7 (31.82%)</td><td align="left">3 (11.11%)</td><td char="." align="char">0.074</td></tr><tr><td align="left">&#x000a0;Diabetes (%)</td><td align="left">4 (18.18%)</td><td align="left">6 (22.22%)</td><td char="." align="char">0.727</td></tr><tr><td align="left">&#x000a0;Malignant tumor (%)</td><td align="left">6 (27.27%)</td><td align="left">3 (11.11%)</td><td char="." align="char">0.146</td></tr><tr><td align="left" colspan="4">Infection site</td></tr><tr><td align="left">&#x000a0;Pneumonia (%)</td><td align="left">5 (22.73%)</td><td align="left">1 (3.70%)</td><td char="." align="char">0.019*</td></tr><tr><td align="left"><p>&#x000a0;Urinary tract</p><p>infection (%)</p></td><td align="left">0 (0.00%)</td><td align="left">3 (11.11%)</td><td char="." align="char">0.107</td></tr><tr><td align="left">&#x000a0;Peritonitis (%)</td><td align="left">17 (77.27%)</td><td align="left">23 (85.19%)</td><td char="." align="char">0.477</td></tr><tr><td align="left"><p>&#x000a0;APACHEII score</p><p>(Mean&#x02009;&#x000b1;&#x02009;SD)</p></td><td align="left">21.09&#x02009;&#x000b1;&#x02009;4.71</td><td align="left">18.33&#x02009;&#x000b1;&#x02009;4.67</td><td char="." align="char">0.046*</td></tr><tr><td align="left"><p>&#x000a0;LIPS score</p><p>(Mean&#x02009;&#x000b1;&#x02009;SD)</p></td><td align="left">9.34&#x02009;&#x000b1;&#x02009;1.62</td><td align="left">6.07&#x02009;&#x000b1;&#x02009;2.61</td><td char="." align="char">0.000**</td></tr><tr><td align="left"><p>&#x000a0;SOFA score</p><p>(Mean&#x02009;&#x000b1;&#x02009;SD)</p></td><td align="left">8.77&#x02009;&#x000b1;&#x02009;2.81</td><td align="left">7.96&#x02009;&#x000b1;&#x02009;2.16</td><td char="." align="char">0.260</td></tr><tr><td align="left"><p>&#x000a0;Pa0<sub>2</sub>/</p><p>FiO<sub>2</sub>(Q1-Q3)</p></td><td align="left">154.00 (114.50, 194.00)</td><td align="left">310.00 (224.00, 388.00)</td><td char="." align="char">0.015*</td></tr><tr><td align="left"><p>&#x000a0;Serum creatinine</p><p>(Q1-Q3)</p></td><td align="left">85.00 (70.00, 118.00)</td><td align="left">85.00 (58.00, 153.00)</td><td char="." align="char">0.599</td></tr><tr><td align="left"><p>&#x000a0;eGFR</p><p>(Mean&#x02009;&#x000b1;&#x02009;SD)</p></td><td align="left">67.57&#x02009;&#x000b1;&#x02009;28.88</td><td align="left">73.93&#x02009;&#x000b1;&#x02009;45.34</td><td char="." align="char">0.552</td></tr><tr><td align="left" colspan="4">Methods of respiratory support</td></tr><tr><td align="left"><p>&#x000a0;Oxygen inhalation through</p><p>the nasal tube(%)</p></td><td align="left">5 (22.73%)</td><td align="left">4 (14.81%)</td><td char="." align="char">0.477</td></tr><tr><td align="left"><p>&#x000a0;Noninvasive mechanical</p><p>ventilation (%)</p></td><td align="left">2 (9.09%)</td><td align="left">2(7.41%)</td><td char="." align="char">0.830</td></tr><tr><td align="left"><p>&#x000a0;Invasive mechanical</p><p>ventilation (%)</p></td><td align="left">15 (68.18%)</td><td align="left">22 (81.48%)</td><td char="." align="char">0.282</td></tr><tr><td align="left"><p>&#x000a0;Noninvasive and invasive</p><p>mechanical ventilation</p></td><td align="left">4 (18.18%)</td><td align="left">1 (3.70%)</td><td char="." align="char">0.096</td></tr><tr><td align="left">&#x000a0;Use of vasopressors (%)</td><td align="left">20 (90.91%)</td><td align="left">25 (92.59%)</td><td char="." align="char">0.830</td></tr><tr><td align="left">&#x000a0;Use of CRRT (%)</td><td align="left">6 (27.27%)</td><td align="left">8 (29.63%)</td><td char="." align="char">0.856</td></tr><tr><td align="left" colspan="4">Outcome</td></tr><tr><td align="left">&#x000a0;28-day mortality rate (%)</td><td align="left">6 (27.27%)</td><td align="left">1 (3.70%)</td><td char="." align="char">0.019*</td></tr></tbody></table><table-wrap-foot><p>* <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05 ** <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.01.</p></table-wrap-foot></table-wrap>
</p></sec><sec id="Sec10"><title>Urinary GaGs and plasma inflammatory factors of the first day in sepsis patients</title><p id="Par65">Through continuous monitoring of the patients&#x02019; conditions and daily preservation of biological samples, we obtained a total of 49 patients&#x02019; time-series biological samples, including 132 plasma samples and 132 urine samples. On the first day of enrollment, among inflammatory factors, only TNF-&#x003b1; showed a significant difference between the two groups of patients. However, the levels of DS, CS, and HS in urine on the first day were higher in septic patients who later developed ARDS than in those who did not develop ARDS, and the differences were statistically significant. Details are shown in Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>; Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>.To address potential confounding by pulmonary infections, we conducted a sensitivity analysis by excluding patients with pneumonia (<italic>n</italic>&#x02009;=&#x02009;6/49),and found that urinary DS, CS and HS of the first day still showed statistically significant differences when comparing ARDS versus non-ARDS patients (Mann-Whitney U test, DS: <italic>p</italic>&#x02009;=&#x02009;0.001***; CS: <italic>p</italic>&#x02009;=&#x02009;0.010**; HS: <italic>p</italic>&#x02009;=&#x02009;0.017*).</p><p id="Par66">
<table-wrap id="Tab2"><label>Table 2</label><caption><p>Urinary GaGs and plasma inflammatory factors of the first day between two groups.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Variable</th><th align="left">ARDS</th><th align="left">Non-ARDS</th><th align="left"><italic>P</italic>&#x000a0;value</th></tr></thead><tbody><tr><td align="left">DS</td><td align="left"><p>21.45</p><p>(9.49&#x02013;28.96)</p></td><td char="." align="left"><p>6.66</p><p>(3.82&#x02013;10.80)</p></td><td char="." align="char">0.001**</td></tr><tr><td align="left">CS</td><td align="left"><p>32.33</p><p>(17.66&#x02013;66.39)</p></td><td align="left"><p>18.40</p><p>(8.61&#x02013;31.70)</p></td><td char="." align="char">0.027*</td></tr><tr><td align="left">HS</td><td align="left"><p>30.76</p><p>(16.76&#x02013;49.76)</p></td><td align="left"><p>16.10</p><p>(6.75&#x02013;28.58)</p></td><td char="." align="char">0.037*</td></tr><tr><td align="left">IL-1&#x003b2;</td><td char="." align="left"><p>8.82</p><p>(2.51&#x02013;24.28)</p></td><td align="left"><p>17.36</p><p>(9.65&#x02013;100.96)</p></td><td char="." align="char">0.093</td></tr><tr><td align="left">IFN-&#x003b3;</td><td char="." align="left"><p>12.86</p><p>(2.97&#x02013;26.02)</p></td><td align="left"><p>5.40</p><p>(1.87&#x02013;16.91)</p></td><td char="." align="char">0.188</td></tr><tr><td align="left">TNF-&#x003b1;</td><td align="left"><p>35.78</p><p>(11.84&#x02013;77.32)</p></td><td align="left"><p>15.32</p><p>(9.24&#x02013;35.83)</p></td><td char="." align="char">0.027*</td></tr><tr><td align="left">MCP-1</td><td char="." align="left"><p>283.56</p><p>(130.21&#x02013;663.79)</p></td><td char="." align="left"><p>460.04</p><p>(236.17&#x02013;2103.95)</p></td><td char="." align="char">0.159</td></tr><tr><td align="left">IL-6</td><td align="left"><p>331.01</p><p>(93.62&#x02013;1475.63)</p></td><td align="left"><p>282.41</p><p>(125.93&#x02013;1190.90)</p></td><td char="." align="char">0.717</td></tr><tr><td align="left">IL-8</td><td char="." align="left"><p>101.95</p><p>(46.57&#x02013;180.56)</p></td><td char="." align="left"><p>104.24</p><p>(36.11&#x02013;915.81)</p></td><td char="." align="char">0.763</td></tr><tr><td align="left">IL-10</td><td align="left"><p>36.20</p><p>(16.49&#x02013;135.83)</p></td><td align="left"><p>46.19</p><p>(7.41&#x02013;107.61)</p></td><td char="." align="char">0.904</td></tr><tr><td align="left">AngII</td><td align="left"><p>2491.55</p><p>(1318.17&#x02013;4635.21)</p></td><td char="." align="left"><p>3164.35</p><p>(1495.33&#x02013;5167.23)</p></td><td char="." align="char">0.220</td></tr><tr><td align="left">KL-6</td><td align="left"><p>30.90</p><p>(27.02&#x02013;52.14)</p></td><td char="." align="left"><p>31.45</p><p>(27.07&#x02013;37.50)</p></td><td char="." align="char">0.615</td></tr><tr><td align="left">RAGE</td><td char="." align="left"><p>273.81</p><p>(203.13&#x02013;380.84)</p></td><td align="left"><p>288.28</p><p>(149.91&#x02013;387.19)</p></td><td char="." align="char">0.482</td></tr></tbody></table><table-wrap-foot><p>* <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05 ** <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.01.</p></table-wrap-foot></table-wrap>
</p><p id="Par67">
<fig id="Fig4"><label>Fig. 4</label><caption><p>Urinary GAGs of the first day showed significant differences between two groups. * <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05 ** <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.01.</p></caption><graphic xlink:href="41598_2025_2109_Fig4_HTML" id="d33e1276"/></fig>
</p></sec><sec id="Sec11"><title>Relevance between urinary GaGs and clinical parameters</title><p id="Par68">Spearman correlation analysis showed that on the first day, urinary DS, CS, and HS levels correlated with PaO<sub>2</sub>/FiO<sub>2</sub>, LIPS, and SOFA scores, as well as with APACHE II (except for DS) (details are shown in Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5</xref>), indicating that urinary GAGs might reflect the severity of lung injury, organ dysfunction, and disease severity.</p><p id="Par69">
<fig id="Fig5"><label>Fig. 5</label><caption><p>Relevance between urinary GAGs and clinical parameters. * <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05 ** <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.01.</p></caption><graphic xlink:href="41598_2025_2109_Fig5_HTML" id="d33e1304"/></fig>
</p></sec><sec id="Sec12"><title>Parameters screening related to the occurrence of ARDS in patients with sepsis using generalized estimating equation</title><p id="Par70">Because we conducted multiple measurements based on time series for each patient&#x02019;s sample, all variables showing significant differences in Tables&#x000a0;<xref rid="Tab1" ref-type="table">1</xref> and <xref rid="Tab2" ref-type="table">2</xref> were enrolled in multivariable generalized estimating equation. After matching for age, pneumonia, APACHE II, LIPS, and PaO<sub>2</sub>/FiO<sub>2</sub>, DS and TNF-&#x003b1; were shown to be independently associated with the future development of ARDS(Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref>). The variation trends of the three GAGs during the initial three days are additionally displayed in the Fig.&#x000a0;<xref rid="Fig6" ref-type="fig">6</xref>.</p><p id="Par71">
<table-wrap id="Tab3"><label>Table 3</label><caption><p>Results of multivariable generalized estimating equation.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Variable</th><th align="left">B</th><th align="left">Standard error</th><th align="left">95% CI</th><th align="left">Wald &#x003c7;2</th><th align="left"><italic>P</italic> value</th><th align="left">OR</th><th align="left">95% CI</th></tr></thead><tbody><tr><td align="left">Sex</td><td char="." align="char">0.793</td><td char="." align="char">0.8097</td><td align="left">&#x02013; 0.794 to 2.38</td><td char="." align="char">0.958</td><td char="." align="char">0.328</td><td char="." align="char">2.209</td><td align="left">0.452 to 10.801</td></tr><tr><td align="left">Pneumonia</td><td char="." align="char">2.507</td><td char="." align="char">1.3425</td><td align="left">&#x02013; 5.139 to 0.124</td><td char="." align="char">3.488</td><td char="." align="char">0.062</td><td char="." align="char">0.081</td><td char="." align="left">0.006 to 1.132</td></tr><tr><td align="left">APACHEII</td><td char="." align="char">0.154</td><td char="." align="char">0.1025</td><td align="left">&#x02013; 0.047 to 0.355</td><td char="." align="char">2.252</td><td char="." align="char">0.133</td><td char="." align="char">1.166</td><td align="left">0.954 to 1.426</td></tr><tr><td align="left">LIPS</td><td char="." align="char">0.082</td><td char="." align="char">0.1785</td><td align="left">&#x02013; 0.268 to 0.431</td><td char="." align="char">0.209</td><td char="." align="char">0.648</td><td char="." align="char">1.085</td><td char="." align="left">0.765 to 1.539</td></tr><tr><td align="left">PaO<sub>2</sub>/FiO<sub>2</sub></td><td char="." align="char">0.009</td><td char="." align="char">0.0054</td><td align="left">&#x02013; 0.002 to 0.019</td><td char="." align="char">2.477</td><td char="." align="char">0.116</td><td char="." align="char">1.009</td><td align="left">0.998 to 1.019</td></tr><tr><td align="left">DS</td><td char="." align="char">0.087</td><td char="." align="char">0.0314</td><td align="left">0.026 to 0.149</td><td char="." align="char">7.69</td><td char="." align="char">0.006**</td><td char="." align="char">1.091</td><td align="left">1.026 to 1.16</td></tr><tr><td align="left">CS</td><td char="." align="char">-0.002</td><td char="." align="char">0.0274</td><td align="left">&#x02013; 0.056 to 0.051</td><td char="." align="char">0.007</td><td char="." align="char">0.931</td><td char="." align="char">0.998</td><td char="." align="left">0.946 to 1.053</td></tr><tr><td align="left">HS</td><td char="." align="char">0.007</td><td char="." align="char">0.0272</td><td align="left">&#x02013; 0.046 to 0.061</td><td char="." align="char">0.071</td><td char="." align="char">0.79</td><td char="." align="char">1.007</td><td align="left">0.955 to 1.062</td></tr><tr><td align="left">TNF-&#x003b1;</td><td char="." align="char">0.024</td><td char="." align="char">0.0089</td><td align="left">0.007 to 0.042</td><td char="." align="char">7.334</td><td char="." align="char">0.007**</td><td char="." align="char">1.024</td><td align="left">1.007 to 1.042</td></tr></tbody></table><table-wrap-foot><p>* <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05 ** <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.01.</p></table-wrap-foot></table-wrap>
</p><p id="Par72">
<fig id="Fig6"><label>Fig. 6</label><caption><p>The variation trends of the three GAGs during the initial three days. * <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05 ** <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.01***<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.001.</p></caption><graphic xlink:href="41598_2025_2109_Fig6_HTML" id="d33e1550"/></fig>
</p></sec></sec><sec id="Sec13"><title>Discussion</title><p id="Par73">Our study found that in sepsis patients, increased urinary GAGs and plasma TNF-&#x003b1; levels were associated with subsequent ARDS development. Even after adjusting for patients&#x02019; baseline characteristics and initial lung injury severity, urinary DS and plasma TNF-&#x003b1; levels remained independently associated with ARDS occurrence. Therefore, urinary GAGs may represent novel biomarkers for ARDS prediction, and future studies could explore combining urinary GAGs with inflammatory factors to improve ARDS predictive accuracy.</p><p id="Par74">Although the primary sources of infection in sepsis (e.g., pneumonia, peritonitis, pancreatitis) may differ, emerging evidence suggests that glycocalyx degradation follows a shared pathway in ARDS development<sup><xref ref-type="bibr" rid="CR17">17</xref></sup>. In sepsis, the endothelial glycocalyx undergoes progressive degradation through multiple interconnected pathways that ultimately contribute to the development of acute respiratory distress syndrome (ARDS). The process begins when pathogen-associated molecular patterns (PAMPs) and damage-associated molecular patterns (DAMPs) activate Toll-like receptors on immune cells, triggering a cytokine storm characterized by elevated TNF-&#x003b1;, IL-1&#x003b2;, and IL-6<sup><xref ref-type="bibr" rid="CR18">18</xref></sup>. These inflammatory mediators induce glycocalyx breakdown through enzymatic cleavage by upregulating Heparanase(HPA) and matrix metalloproteinases (MMPs)<sup><xref ref-type="bibr" rid="CR19">19</xref>,<xref ref-type="bibr" rid="CR20">20</xref></sup>, particularly MMP-9, which specifically target HS side chains and core proteins like syndecan-1<sup><xref ref-type="bibr" rid="CR21">21</xref></sup>. Concurrently, nicotinamide adenine dinucleotide phosphate (NADPH) oxidase-derived reactive oxygen species (ROS) cause oxidative fragmentation of GAGs polysaccharide chains, while hemodynamic disturbances from microcirculatory failure led to mechanical stripping of the glycocalyx. The shed GAG components, then propagate lung injury through several mechanisms: loss of the glycocalyx barrier exposes endothelial junctions (e.g., VE-cadherin) and increases vascular permeability; Circulating HS potentiates vascular endothelial growth factor (VEGF)-mediated leakage; Unmasked adhesion molecules promote neutrophil recruitment; Shed DS acts as a DAMP that activates Toll-Like Receptor 4(TLR4) on neutrophils, triggering neutrophil extracellular trap (NET) release and further inflammation. Additionally, depletion of HS-bound antithrombin III (ATIII) sites disrupts thrombin regulation, leading to microthrombosis that compounds pulmonary vascular injury<sup><xref ref-type="bibr" rid="CR4">4</xref></sup>. The pulmonary vasculature is particularly vulnerable to these effects due to its unique anatomical and physiological characteristics - the immense alveolar-capillary surface area (~&#x02009;70&#x000a0;m<sup>2</sup>), exceptionally thin endothelial layer (0.1&#x02013;0.2&#x000a0;&#x003bc;m), and low-pressure circulation make the lung highly dependent on an intact glycocalyx for maintaining barrier function<sup><xref ref-type="bibr" rid="CR17">17</xref></sup>. This vulnerability explains why systemic glycocalyx degradation, as reflected by urinary GAG excretion, often manifests first and most severely as ARDS, even when the primary infection originates outside the lungs.</p><p id="Par75">Previously, Murphy&#x02019;s research showed that the extent of endothelial glycocalyx degradation (measured by a component named Syndecan 1) is associated with non-pulmonary organ dysfunction in subjects with sepsis and is associated with ARDS but only in the subgroup with non-pulmonary sepsis<sup><xref ref-type="bibr" rid="CR22">22</xref></sup>. In our study, we used LC-MS to measure urinary GAGs in time-series samples and found that the onset of ARDS in all sepsis patients was associated with an early increase in urinary GAGs, especially DS, compared with non-ARDS sepsis patients. Research has confirmed that different pathophysiologic insults produce characteristic patterns of released glycocalyx fragments<sup><xref ref-type="bibr" rid="CR23">23</xref></sup>, and different types of GAGs may have different shedding periods. Although HS tends to be emphasized as the most biologically active glycosaminoglycan, and it has been discovered that pulmonary endothelial glycocalyx degradation increases neutrophil adhesion and propagates lung injury in a Heparanase-2 dependent fashion<sup><xref ref-type="bibr" rid="CR24">24</xref></sup>, heparin is largely confined to mast cells, whereas DS is a ubiquitous element of the extracellular matrix<sup><xref ref-type="bibr" rid="CR25">25</xref></sup>. Growing evidence suggests DS is an important co-factor in a variety of cell behaviors like cardiovascular disease, tumorigenesis, infection, wound repair, and fibrosis. What&#x02019;s more, Schmidt used HS and CS to predict renal dysfunction in septic shock and ARDS patients, showing that patients who later developed AKI had significantly elevated urinary total glycosaminoglycans at Day 0 and 3, largely derived from consistently elevated urinary CS<sup><xref ref-type="bibr" rid="CR13">13</xref></sup>. CS and DS are stereoisomers and therefore have similar structures<sup><xref ref-type="bibr" rid="CR26">26</xref></sup>. In our research, DS performed better in predicting ARDS, which might suggest that CS is mainly related to kidney injury<sup><xref ref-type="bibr" rid="CR27">27</xref>,<xref ref-type="bibr" rid="CR28">28</xref></sup>.</p><p id="Par76">In addition, we found correlations between urinary GAGs and clinical parameters (PaO<sub>2</sub>/FiO<sub>2</sub>, LIPS, SOFA, and APACHE II) on the first day after admission to SICU, showing that urinary GAGs could reflect pulmonary and other organ dysfunction, indicating urinary GAGs have a close correlation with organ function.</p><p id="Par77">Then, it was found that urinary GAGs and related sulfated disaccharide indexes in ARDS patients were related to hospital mortality<sup><xref ref-type="bibr" rid="CR13">13</xref></sup>. In our study, 28-day mortality differed between ARDS and non-ARDS patients, but we did not focus on the predictive value of urinary GAGs for mortality. Further studies should be conducted to determine whether they could be predictive biomarkers of mortality in sepsis patients.</p><p id="Par78">When it comes to inflammatory factors, inflammatory storm is considered as one of the important causes leading to the occurrence of ARDS. In recent years, more and more studies have attempted to predict the occurrence of ARDS using inflammatory factors in plasma. Meanwhile, studies have also shown that there is an interaction between inflammatory factors and GAGs. Fahlgren found that IFN-&#x003b3;-induced cell maturation would lead to more carcinoembryonic antigen (CEA) and carcinoembryonic antigen-related cell adhesion molecule 6 (CEACAM6, localized to the apical glycocalyx of normal colonic epithelium and suggested to play a role in innate immunity) in glycocalyx layers. This would be helpful from the point of view of immune defense, because bacteria would be entrapped at a distance from the epithelial cell surface, providing further protection<sup><xref ref-type="bibr" rid="CR29">29</xref></sup>. The mast cell IFN-&#x003b3; binding element was identified as DS<sup><xref ref-type="bibr" rid="CR30">30</xref></sup>. GAGs are known to bind IFN-&#x003b3; to protect it from degradation and increase its half-life, prolonging its pro-inflammatory effects<sup><xref ref-type="bibr" rid="CR31">31</xref></sup>. TNF-&#x003b1; is also a central factor in cytokine storm. Schmidt&#x02019;s research showed that TNF-&#x003b1; was one of the factors that could damage the glycocalyx during inflammatory diseases through HPA<sup><xref ref-type="bibr" rid="CR32">32</xref></sup>, and studies have shown that shedding of the glycocalyx decreased with etanercept (TNF-&#x003b1; antagonist) in adult volunteers<sup><xref ref-type="bibr" rid="CR33">33</xref></sup>. Chemokines and GAGs interact to localize chemokines to inflammatory environments where they are produced<sup><xref ref-type="bibr" rid="CR34">34</xref></sup>. IL-8 also binds CS/DS in arthritis, acute nephritis, sepsis, and ischemia-reperfusion injury in brain, etc<sup><xref ref-type="bibr" rid="CR35">35</xref></sup>. Ang II is also a purported causative agent for endothelial glycocalyx breakdown<sup><xref ref-type="bibr" rid="CR36">36</xref></sup>. Lukasz found that Ang II treatment causes rapid degradation of endothelial glycocalyx both in vivo and in vitro, using a human umbilical vein endothelial cell line and mice<sup><xref ref-type="bibr" rid="CR36">36</xref></sup>. Urinary GAG levels correlated significantly with plasma Ang II in Falciparum malaria<sup><xref ref-type="bibr" rid="CR37">37</xref></sup>. RAGE was found to be associated with airspace GAG levels<sup><xref ref-type="bibr" rid="CR9">9</xref></sup>, and DS, CS and HS might play roles in RAGE-mediated cell signaling, tumor metastasis, and other biological phenomena<sup><xref ref-type="bibr" rid="CR38">38</xref></sup>. More research is needed to find out the interaction mechanism between inflammatory factors and GAGs.</p><p id="Par79">We know that vascular glycocalyx is one of the earliest sites influenced by inflammation<sup><xref ref-type="bibr" rid="CR39">39</xref></sup>. The function of the glycocalyx depends on its structural integrity. In sepsis, the glycocalyx sheds due to inflammation, leading to a series of pathological changes, including increased vascular permeability, changes in vascular tension, disorder of the coagulation system and antioxidant system, and adhesion between leukocytes and vascular endothelial cells<sup><xref ref-type="bibr" rid="CR39">39</xref></sup>.</p><p id="Par80">Notably, GAGs, AngII, and RAGE are all biomarkers reflecting endothelial or epithelial cell injury, but compared to Ang II and RAGE, GAGs offer distinct advantages for early ARDS recognition, particularly due to their direct association with endothelial glycocalyx degradation&#x02014;a process that precedes clinical manifestations of lung injury<sup><xref ref-type="bibr" rid="CR40">40</xref></sup>. While Ang II primarily reflects generalized endothelial activation and RAGE indicates established alveolar epithelial damage, urinary GAGs (especially DS and HS) serve as real-time indicators of vascular barrier disruption, detectable even before overt hypoxemia develops<sup><xref ref-type="bibr" rid="CR41">41</xref></sup>.Key strengths of GAGs include temporal sensitivity: GAG shedding occurs early in the &#x0201c;two-hit&#x0201d; model of ARDS (initial endothelial injury followed by inflammation), whereas Ang II peaks later during cytokine storms, and RAGE rises predominantly after epithelial injury; Organ Specificity: Unlike Ang II (systemic endothelial dysfunction), GAGs like DS show stronger correlations with pulmonary vascular injury (e.g., higher LIPS scores and PaO<sub>2</sub>/FiO<sub>2</sub> decline); Non-Invasive Monitoring: Urinary GAGs enable serial assessments without invasive procedures (e.g., Bronchoalveolar lavage or plasma for RAGE)<sup><xref ref-type="bibr" rid="CR40">40</xref></sup>, critical for ICU patients. Thus, while Ang II and RAGE remain valuable for disease staging, GAGs provide a unique window into the earliest phases of ARDS pathogenesis, potentially enabling preemptive interventions.</p><p id="Par81">Based on the above background, in this study, we attempted to combine GAGs with inflammatory factors to observe their relationship with ARDS occurrence. In the univariate analysis, urinary DS, CS, HS, and plasma TNF-&#x003b1; were associated with ARDS occurrence. When these factors were simultaneously included in the generalized estimating equation along with baseline data that showed significant differences, we found that only urinary DS and plasma TNF-&#x003b1; were independently associated with ARDS onset in sepsis patients.</p><p id="Par82">It should be emphasized that our study population differs from traditional ARDS cohorts in medical ICUs, as we specifically focused on surgical patients with sepsis. This population represents a unique clinical entity where the pathophysiology of ARDS may be influenced by both the primary infectious process and surgical trauma. This study observed a relatively high proportion of peritonitis as the primary infection source, which differs from traditional ARDS studies where pulmonary infections predominantly prevail. However, this distribution pattern closely aligns with epidemiological data on sepsis in surgical ICUs, multiple studies report that intra-abdominal infections account for 40&#x02013;60% of sepsis cases in SICU populations<sup><xref ref-type="bibr" rid="CR42">42</xref></sup>.This discrepancy precisely reflects the unique characteristics of surgical patients with sepsis.</p><p id="Par83">Taking all the findings into consideration, GAGs may be a novel therapeutic target in sepsis and ARDS. The treatment directions can be divided into inhibiting the degradation of GAGs and promoting their regeneration. Some studies have focused on therapy targeting the endothelial glycocalyx, such as therapeutic plasma exchange, glucocorticoids, heparinoid preparations, and vascular endothelial growth factor, etc<sup><xref ref-type="bibr" rid="CR43">43</xref>&#x02013;<xref ref-type="bibr" rid="CR46">46</xref></sup>. Further research is needed to establish a complete, highly specific preventive and treatment strategy for ARDS.</p><p id="Par84">Our study is the first to evaluate the predictive value of DS, CS and HS for ARDS in sepsis patients. Our research was performed using an LC-MS system. Another study has shown that LC-MS results could be largely replicated using an inexpensive, rapidly performed colorimetric assay of sulfated glycosaminoglycans<sup><xref ref-type="bibr" rid="CR13">13</xref></sup>.Preliminary data suggest urinary GAGs as candidate biomarkers, but their clinical utility requires validation in independent cohorts.</p><p id="Par85">Although strict inclusion and exclusion criteria were used in the present study to find correlation between onset of ARDS and urinary GAGs in sepsis patients, our study had several limitations. (1) The sample size was small, and we did not analyze HA or KS, which may have additional predictive value. However, our pilot data on DS/CS/HS provide a foundation for subsequent expanded panels. While our study identified urinary GAGs as potential ARDS biomarkers, we acknowledge that the mixed etiology and different severity levels of our cohort may introduce confounding effects. We need more samples and multicenter studies to expand and verify our conclusions. (2) We only identified novel biomarkers associated with ARDS occurrence but did not establish a predictive model for ARDS. (3) More basic experiments are needed to investigate the correlation between urinary GAGs and plasma inflammatory factors. Nevertheless, our study has several strengths: (1) No previous studies have focused on the predictive value of urinary DS for ARDS; (2) Samples collected before ARDS diagnosis made our predictive results more reliable; (3) We established time-series data by collecting samples consecutively and used generalized estimating equations instead of logistic regression to account for temporal correlations among repeated laboratory measurements.</p></sec><sec id="Sec14"><title>Conclusions</title><p id="Par86">In our dynamic study cohort, we found an association between levels of urinary DS, CS, and HS measured by LC-MS and subsequent ARDS onset in sepsis patients. Urinary GAGs correlated with PaO<sub>2</sub>/FiO<sub>2</sub>, LIPS, SOFA, and APACHEII scores. DS and TNF-&#x003b1; show promise as early ARDS biomarkers in septic patients, but their generalizability across ARDS subtypes requires further validation. Future multicenter studies should prioritize etiology-specific enrollment to establish clinical utility.</p></sec><sec id="Sec15" sec-type="supplementary-material"><title>Electronic supplementary material</title><p>Below is the link to the electronic supplementary material.</p><p>
<supplementary-material content-type="local-data" id="MOESM1"><media xlink:href="41598_2025_2109_MOESM1_ESM.doc"><caption><p>Supplementary Material 1</p></caption></media></supplementary-material>
</p></sec></body><back><glossary><title>Abbreviations</title><def-list><def-item><term>ARDS</term><def><p id="Par2">Acute respiratory distress syndrome</p></def></def-item><def-item><term>GAGs</term><def><p id="Par3">Glycosaminoglycans</p></def></def-item><def-item><term>LIPS</term><def><p id="Par4">Lung injury prediction score</p></def></def-item><def-item><term>ALI</term><def><p id="Par5">Acute lung injury</p></def></def-item><def-item><term>CS</term><def><p id="Par6">Chondroitin sulfate</p></def></def-item><def-item><term>DS</term><def><p id="Par7">Dermatan sulfate</p></def></def-item><def-item><term>HS</term><def><p id="Par8">Heparan sulfate</p></def></def-item><def-item><term>KS</term><def><p id="Par9">Keratan sulfate</p></def></def-item><def-item><term>HA</term><def><p id="Par10">Hyaluronan</p></def></def-item><def-item><term>SICU</term><def><p id="Par11">Surgical intensive care unit</p></def></def-item><def-item><term>IFN-&#x003b3;</term><def><p id="Par12">Interferon-&#x003b3;</p></def></def-item><def-item><term>TNF-&#x003b1;</term><def><p id="Par13">Tumor necrosis factor-&#x003b1;</p></def></def-item><def-item><term>MCP-1</term><def><p id="Par14">Monocyte chemoattractant protein-1</p></def></def-item><def-item><term>IL-6</term><def><p id="Par15">Interleukin-6</p></def></def-item><def-item><term>IL-8</term><def><p id="Par16">Interleukin-8</p></def></def-item><def-item><term>IL-10</term><def><p id="Par17">Interleukin-10</p></def></def-item><def-item><term>AngII</term><def><p id="Par18">AngiopoietinII</p></def></def-item><def-item><term>KL-6</term><def><p id="Par19">Krebs von den Lungen-6</p></def></def-item><def-item><term>RAGE</term><def><p id="Par20">Receptor for advanced glycation end products</p></def></def-item><def-item><term>CRF</term><def><p id="Par21">Case report forms</p></def></def-item><def-item><term>APACHE II</term><def><p id="Par22">Acute physiology and chronic health evaluation II</p></def></def-item><def-item><term>SOFA</term><def><p id="Par23">Sequential organ failure assessment</p></def></def-item><def-item><term>SD</term><def><p id="Par24">Standard deviation</p></def></def-item><def-item><term>CI</term><def><p id="Par25">Confidence interval</p></def></def-item><def-item><term>eGFR</term><def><p id="Par26">Estimated glomerular filtration rate</p></def></def-item><def-item><term>PAMPs</term><def><p id="Par27">Pathogen-associated molecular patterns</p></def></def-item><def-item><term>DAMPs</term><def><p id="Par28">Damage-associated molecular patterns</p></def></def-item><def-item><term>HPA</term><def><p id="Par29">Heparanase</p></def></def-item><def-item><term>MMPs</term><def><p id="Par30">Matrix metalloproteinases</p></def></def-item><def-item><term>NADPH</term><def><p id="Par31">Nicotinamide adenine dinucleotide phosphate</p></def></def-item><def-item><term>ROS</term><def><p id="Par32">Reactive oxygen species</p></def></def-item><def-item><term>VEGF</term><def><p id="Par33">Vascular endothelial growth factor</p></def></def-item><def-item><term>TLR4</term><def><p id="Par34">Toll-Like Receptor 4</p></def></def-item><def-item><term>NET</term><def><p id="Par35">Neutrophil extracellular trap</p></def></def-item><def-item><term>AT III</term><def><p id="Par36">Antithrombin III</p></def></def-item><def-item><term>CEA</term><def><p id="Par37">Carcinoembryonic antigen</p></def></def-item></def-list></glossary><fn-group><fn><p><bold>Publisher&#x02019;s note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn><fn><p>Ziyuan Shen, Zhengying Li, Hua Zhang and Xiaoyun Wei contributed equally to this work.</p></fn></fn-group><notes notes-type="author-contribution"><title>Author contributions</title><p>ZY.S., ZY.L., H.Z. and XY.W. contributed equally to this work. ZY.S., X.Z. and C.T. designed this work. SH.W., F.Z. and C.Y. collected samples and clinical parameters of patients. ZY.L., ZN.Y. and CC.D. measured urinary GAGs and plasma inflammatory factors. H.Z., ZY.S. and XY.W. analyzed the statistics. ZY.S. and ZK.C. wrote this paper. All authors read and approved the final manuscript.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>This study was funded by Capital Health Research and Development of Special Fund (Grant/Award 2020-2-4094), Peking University Third Hospital Cohort Study Project (BYSYDL2021010) and Beijing Municipal Natural Science Foundation (Grant/Award 7212130), National Natural Science Foundation of China (Grant/Award 82172166). Key Clinical Projects of Peking University Third Hospital (BYSYZD2023012).</p></notes><notes notes-type="data-availability"><title>Data availability</title><p>The datasets generated during and/or analysed during the current study are available from the corresponding author on reasonable request.</p></notes><notes id="FPar1" notes-type="COI-statement"><title>Competing interests</title><p id="Par87">The authors declare no competing interests.</p></notes><notes id="FPar2"><title>Ethics approval</title><p id="Par88">The studies involving human participants were reviewed and approved by institutional review boards of Peking University Third Hospital (Beijing China) (ethics number M2020278). Written informed consent was obtained from each patient or a relative.</p></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><mixed-citation publication-type="other">Singer, M. et al. The third international consensus definitions for Sepsis and septic shock (Sepsis-3). <italic>Jama</italic><bold>2016</bold>, 315 (2016).</mixed-citation></ref><ref id="CR2"><label>2.</label><citation-alternatives><element-citation id="ec-CR2" publication-type="journal"><person-group person-group-type="author"><name><surname>Banavasi</surname><given-names>H</given-names></name><name><surname>Osman</surname><given-names>NP</given-names></name><name><surname>Soubani</surname><given-names>H</given-names></name></person-group><article-title>Management of ARDS &#x02013; what works and what does not</article-title><source>Am. J. Med. Sci.</source><year>2021</year><volume>362</volume><fpage>13</fpage><lpage>23</lpage><pub-id pub-id-type="doi">10.1016/j.amjms.2020.12.019</pub-id><pub-id pub-id-type="pmid">34090669</pub-id>
</element-citation><mixed-citation id="mc-CR2" publication-type="journal">Banavasi, H., Osman, N. P. &#x00026; Soubani, H. Management of ARDS &#x02013; what works and what does not. <italic>Am. J. Med. Sci.</italic><bold>362</bold>, 13&#x02013;23 (2021).<pub-id pub-id-type="pmid">34090669</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR3"><label>3.</label><mixed-citation publication-type="other">Uchimido, R., Schmidt, E. P. &#x00026; Shapiro, N. I. The glycocalyx: a novel diagnostic and therapeutic target in sepsis. <italic>Crit. Care</italic><bold>23</bold>, 456 (2019).</mixed-citation></ref><ref id="CR4"><label>4.</label><citation-alternatives><element-citation id="ec-CR4" publication-type="journal"><person-group person-group-type="author"><name><surname>Jedlicka</surname><given-names>J</given-names></name><name><surname>Becker</surname><given-names>BF</given-names></name><name><surname>Chappell</surname><given-names>D</given-names></name></person-group><article-title>Endothelial glycocalyx</article-title><source>Crit. Care Clin.</source><year>2020</year><volume>36</volume><fpage>217</fpage><lpage>232</lpage><pub-id pub-id-type="doi">10.1016/j.ccc.2019.12.007</pub-id><pub-id pub-id-type="pmid">32172810</pub-id>
</element-citation><mixed-citation id="mc-CR4" publication-type="journal">Jedlicka, J., Becker, B. F. &#x00026; Chappell, D. Endothelial glycocalyx. <italic>Crit. Care Clin.</italic><bold>36</bold>, 217&#x02013;232 (2020).<pub-id pub-id-type="pmid">32172810</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR5"><label>5.</label><mixed-citation publication-type="other">LaRivi&#x000e8;re, W. B. &#x00026; Schmidt, E. P. in <italic>Membranes in Pulmonary Vascular Disease Current Topics in Membranes</italic> 33&#x02013;52 (2018).</mixed-citation></ref><ref id="CR6"><label>6.</label><citation-alternatives><element-citation id="ec-CR6" publication-type="journal"><person-group person-group-type="author"><name><surname>Kozar</surname><given-names>RA</given-names></name><name><surname>Pati</surname><given-names>S</given-names></name></person-group><article-title>Syndecan-1 restitution by plasma after hemorrhagic shock</article-title><source>J. Trauma. Acute Care Surg.</source><year>2015</year><volume>78</volume><fpage>S83</fpage><lpage>S86</lpage><pub-id pub-id-type="doi">10.1097/TA.0000000000000631</pub-id><pub-id pub-id-type="pmid">26002270</pub-id>
</element-citation><mixed-citation id="mc-CR6" publication-type="journal">Kozar, R. A. &#x00026; Pati, S. Syndecan-1 restitution by plasma after hemorrhagic shock. <italic>J. Trauma. Acute Care Surg.</italic><bold>78</bold>, S83&#x02013;S86 (2015).<pub-id pub-id-type="pmid">26002270</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR7"><label>7.</label><mixed-citation publication-type="other">Garc&#x000ed;a-Ortiz, A. &#x00026; Serrador, J. M. ERM proteins at the crossroad of leukocyte polarization, migration and intercellular adhesion. <italic>Int. J. Mol. Sci.</italic><bold>21</bold>, 123 (2020).</mixed-citation></ref><ref id="CR8"><label>8.</label><citation-alternatives><element-citation id="ec-CR8" publication-type="journal"><person-group person-group-type="author"><name><surname>Curry</surname><given-names>FE</given-names></name></person-group><article-title>Layer upon layer: the functional consequences of disrupting the glycocalyx-endothelial barrier in vivo and in vitro</article-title><source>Cardiovasc. Res.</source><year>2017</year><volume>113</volume><fpage>559</fpage><lpage>561</lpage><pub-id pub-id-type="doi">10.1093/cvr/cvx044</pub-id><pub-id pub-id-type="pmid">28453735</pub-id>
</element-citation><mixed-citation id="mc-CR8" publication-type="journal">Curry, F. E. Layer upon layer: the functional consequences of disrupting the glycocalyx-endothelial barrier in vivo and in vitro. <italic>Cardiovasc. Res.</italic><bold>113</bold>, 559&#x02013;561 (2017).<pub-id pub-id-type="pmid">28453735</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR9"><label>9.</label><mixed-citation publication-type="other">Rizzo, A. N. et al. Alveolar epithelial glycocalyx degradation mediates surfactant dysfunction and contributes to acute respiratory distress syndrome. <italic>JCI Insight</italic><bold>7</bold>, 369 (2022).</mixed-citation></ref><ref id="CR10"><label>10.</label><mixed-citation publication-type="other">Nikitovic, D. &#x00026; P&#x000e9;rez, S. Preface for the special issue on the exploration of the multifaceted roles of glycosaminoglycans: gags. <italic>Biomolecules</italic><bold>11</bold>, 25 (2021).</mixed-citation></ref><ref id="CR11"><label>11.</label><mixed-citation publication-type="other">Queisser, K. A. et al. COVID-19 generates hyaluronan fragments that directly induce endothelial barrier dysfunction. <italic>JCI Insight</italic><bold>6</bold>, 14 (2021).</mixed-citation></ref><ref id="CR12"><label>12.</label><citation-alternatives><element-citation id="ec-CR12" publication-type="journal"><person-group person-group-type="author"><name><surname>Carmichael</surname><given-names>SP</given-names></name><etal/></person-group><article-title>Endothelial glycocalyx shedding in Intra-Abdominal sepsis: a feasibility study</article-title><source>Shock</source><year>2023</year><volume>59</volume><fpage>540</fpage><lpage>546</lpage><pub-id pub-id-type="doi">10.1097/SHK.0000000000002079</pub-id><pub-id pub-id-type="pmid">36625488</pub-id>
</element-citation><mixed-citation id="mc-CR12" publication-type="journal">Carmichael, S. P. et al. Endothelial glycocalyx shedding in Intra-Abdominal sepsis: a feasibility study. <italic>Shock</italic><bold>59</bold>, 540&#x02013;546 (2023).<pub-id pub-id-type="pmid">36625488</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR13"><label>13.</label><citation-alternatives><element-citation id="ec-CR13" publication-type="journal"><person-group person-group-type="author"><name><surname>Schmidt</surname><given-names>EP</given-names></name><etal/></person-group><article-title>Urinary glycosaminoglycans predict outcomes in septic shock and acute respiratory distress syndrome</article-title><source>Am. J. Respir. Crit Care Med.</source><year>2016</year><volume>194</volume><fpage>439</fpage><lpage>449</lpage><pub-id pub-id-type="doi">10.1164/rccm.201511-2281OC</pub-id><pub-id pub-id-type="pmid">26926297</pub-id>
</element-citation><mixed-citation id="mc-CR13" publication-type="journal">Schmidt, E. P. et al. Urinary glycosaminoglycans predict outcomes in septic shock and acute respiratory distress syndrome. <italic>Am. J. Respir. Crit Care Med.</italic><bold>194</bold>, 439&#x02013;449 (2016).<pub-id pub-id-type="pmid">26926297</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR14"><label>14.</label><citation-alternatives><element-citation id="ec-CR14" publication-type="journal"><person-group person-group-type="author"><name><surname>Bossuyt</surname><given-names>PM</given-names></name><name><surname>Gatsonis</surname><given-names>CJ</given-names></name><name><surname>Korevaar</surname><given-names>CA</given-names></name><collab>STARD group</collab></person-group><article-title>STARD 2015: updated reporting guidelines for all diagnostic accuracy studies</article-title><source>Ann. Transl. Med.</source><year>2016</year><volume>4</volume><fpage>85</fpage><pub-id pub-id-type="pmid">27004232</pub-id>
</element-citation><mixed-citation id="mc-CR14" publication-type="journal">Bossuyt, P. M., Gatsonis, C. J., Korevaar, C. A. &#x00026; STARD group. STARD 2015: updated reporting guidelines for all diagnostic accuracy studies. <italic>Ann. Transl. Med.</italic><bold>4</bold>, 85 (2016).<pub-id pub-id-type="pmid">27004232</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR15"><label>15.</label><citation-alternatives><element-citation id="ec-CR15" publication-type="journal"><person-group person-group-type="author"><name><surname>Rhodes</surname><given-names>A</given-names></name><etal/></person-group><article-title>Surviving Sepsis campaign: international guidelines for management of Sepsis and septic shock: 2016</article-title><source>Intensive Care Med.</source><year>2017</year><volume>43</volume><fpage>304</fpage><lpage>377</lpage><pub-id pub-id-type="doi">10.1007/s00134-017-4683-6</pub-id><pub-id pub-id-type="pmid">28101605</pub-id>
</element-citation><mixed-citation id="mc-CR15" publication-type="journal">Rhodes, A. et al. Surviving Sepsis campaign: international guidelines for management of Sepsis and septic shock: 2016. <italic>Intensive Care Med.</italic><bold>43</bold>, 304&#x02013;377 (2017).<pub-id pub-id-type="pmid">28101605</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR16"><label>16.</label><citation-alternatives><element-citation id="ec-CR16" publication-type="journal"><person-group person-group-type="author"><collab>ARDS Definition Task Force</collab><name><surname>Rubenfeld</surname><given-names>RV</given-names></name></person-group><article-title>Acute respiratory distress syndrome: the Berlin definition</article-title><source>Jama</source><year>2012</year><volume>307</volume><fpage>2526</fpage><lpage>2533</lpage><pub-id pub-id-type="pmid">22797452</pub-id>
</element-citation><mixed-citation id="mc-CR16" publication-type="journal">ARDS Definition Task Force &#x00026; Rubenfeld, R. V. Acute respiratory distress syndrome: the Berlin definition. <italic>Jama</italic><bold>307</bold>, 2526&#x02013;2533 (2012).<pub-id pub-id-type="pmid">22797452</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR17"><label>17.</label><citation-alternatives><element-citation id="ec-CR17" publication-type="journal"><person-group person-group-type="author"><name><surname>Kravitz</surname><given-names>MS</given-names></name><etal/></person-group><article-title>Plasma for prevention and treatment of glycocalyx degradation in trauma and sepsis</article-title><source>Crit. Care</source><year>2024</year><volume>28</volume><fpage>254</fpage><pub-id pub-id-type="doi">10.1186/s13054-024-05026-7</pub-id><pub-id pub-id-type="pmid">39033135</pub-id>
</element-citation><mixed-citation id="mc-CR17" publication-type="journal">Kravitz, M. S. et al. Plasma for prevention and treatment of glycocalyx degradation in trauma and sepsis. <italic>Crit. Care</italic><bold>28</bold>, 254 (2024).<pub-id pub-id-type="pmid">39033135</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR18"><label>18.</label><citation-alternatives><element-citation id="ec-CR18" publication-type="journal"><person-group person-group-type="author"><name><surname>Goodall</surname><given-names>KJ</given-names></name><name><surname>Poon</surname><given-names>IK</given-names></name><name><surname>Phipps</surname><given-names>S</given-names></name><name><surname>Hulett</surname><given-names>MD</given-names></name></person-group><article-title>Soluble Heparan sulfate fragments generated by Heparanase trigger the release of pro-inflammatory cytokines through TLR-4</article-title><source>PLoS One</source><year>2014</year><volume>9</volume><fpage>e109596</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0109596</pub-id><pub-id pub-id-type="pmid">25295599</pub-id>
</element-citation><mixed-citation id="mc-CR18" publication-type="journal">Goodall, K. J., Poon, I. K., Phipps, S. &#x00026; Hulett, M. D. Soluble Heparan sulfate fragments generated by Heparanase trigger the release of pro-inflammatory cytokines through TLR-4. <italic>PLoS One</italic>. <bold>9</bold>, e109596 (2014).<pub-id pub-id-type="pmid">25295599</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR19"><label>19.</label><citation-alternatives><element-citation id="ec-CR19" publication-type="journal"><person-group person-group-type="author"><name><surname>Masola</surname><given-names>V</given-names></name><name><surname>Zaza</surname><given-names>G</given-names></name><name><surname>Gambaro</surname><given-names>G</given-names></name><name><surname>Franchi</surname><given-names>M</given-names></name><name><surname>Onisto</surname><given-names>M</given-names></name></person-group><article-title>Role of heparanase in tumor progression: molecular aspects and therapeutic options</article-title><source>Semin Cancer Biol.</source><year>2020</year><volume>62</volume><fpage>86</fpage><lpage>98</lpage><pub-id pub-id-type="doi">10.1016/j.semcancer.2019.07.014</pub-id><pub-id pub-id-type="pmid">31348993</pub-id>
</element-citation><mixed-citation id="mc-CR19" publication-type="journal">Masola, V., Zaza, G., Gambaro, G., Franchi, M. &#x00026; Onisto, M. Role of heparanase in tumor progression: molecular aspects and therapeutic options. <italic>Semin Cancer Biol.</italic><bold>62</bold>, 86&#x02013;98 (2020).<pub-id pub-id-type="pmid">31348993</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR20"><label>20.</label><mixed-citation publication-type="other">Bogner-Flatz, V. et al. On-the-scene hyaluronan and syndecan-1 serum concentrations and outcome after cardiac arrest and resuscitation. <italic>Mediators Inflamm.</italic><bold>2019</bold>, 8071619 (2019).</mixed-citation></ref><ref id="CR21"><label>21.</label><citation-alternatives><element-citation id="ec-CR21" publication-type="journal"><person-group person-group-type="author"><name><surname>Murphy</surname><given-names>LS</given-names></name><etal/></person-group><article-title>Endothelial glycocalyx degradation is more severe in patients with non-pulmonary sepsis compared to pulmonary sepsis and associates with risk of ARDS and other organ dysfunction</article-title><source>Ann. Intensive Care</source><year>2017</year><volume>7</volume><fpage>102</fpage><pub-id pub-id-type="doi">10.1186/s13613-017-0325-y</pub-id><pub-id pub-id-type="pmid">28986821</pub-id>
</element-citation><mixed-citation id="mc-CR21" publication-type="journal">Murphy, L. S. et al. Endothelial glycocalyx degradation is more severe in patients with non-pulmonary sepsis compared to pulmonary sepsis and associates with risk of ARDS and other organ dysfunction. <italic>Ann. Intensive Care</italic>. <bold>7</bold>, 102 (2017).<pub-id pub-id-type="pmid">28986821</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR22"><label>22.</label><mixed-citation publication-type="other">Murphy, L. S. et al. Endothelial glycocalyx degradation is more severe in patients with non-pulmonary sepsis compared to pulmonary sepsis and associates with risk of ARDS and other organ dysfunction. <italic>Ann. Intensive Care</italic><bold>7</bold>, 859 (2017).</mixed-citation></ref><ref id="CR23"><label>23.</label><citation-alternatives><element-citation id="ec-CR23" publication-type="journal"><person-group person-group-type="author"><name><surname>Schmidt</surname><given-names>EP</given-names></name><etal/></person-group><article-title>The Circulating glycosaminoglycan signature of respiratory failure in critically ill adults</article-title><source>J. Biol. Chem.</source><year>2014</year><volume>289</volume><fpage>8194</fpage><lpage>8202</lpage><pub-id pub-id-type="doi">10.1074/jbc.M113.539452</pub-id><pub-id pub-id-type="pmid">24509853</pub-id>
</element-citation><mixed-citation id="mc-CR23" publication-type="journal">Schmidt, E. P. et al. The Circulating glycosaminoglycan signature of respiratory failure in critically ill adults. <italic>J. Biol. Chem.</italic><bold>289</bold>, 8194&#x02013;8202 (2014).<pub-id pub-id-type="pmid">24509853</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR24"><label>24.</label><citation-alternatives><element-citation id="ec-CR24" publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>L</given-names></name><etal/></person-group><article-title>Ulinastatin attenuates pulmonary endothelial glycocalyx damage and inhibits endothelial heparanase activity in LPS-induced ARDS</article-title><source>Biochem. Biophys. Res. Commun.</source><year>2016</year><volume>478</volume><fpage>669</fpage><lpage>675</lpage><pub-id pub-id-type="doi">10.1016/j.bbrc.2016.08.005</pub-id><pub-id pub-id-type="pmid">27498004</pub-id>
</element-citation><mixed-citation id="mc-CR24" publication-type="journal">Wang, L. et al. Ulinastatin attenuates pulmonary endothelial glycocalyx damage and inhibits endothelial heparanase activity in LPS-induced ARDS. <italic>Biochem. Biophys. Res. Commun.</italic><bold>478</bold>, 669&#x02013;675 (2016).<pub-id pub-id-type="pmid">27498004</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR25"><label>25.</label><citation-alternatives><element-citation id="ec-CR25" publication-type="journal"><person-group person-group-type="author"><name><surname>Trowbridge</surname><given-names>JM</given-names></name></person-group><article-title>Dermatan sulfate new functions from an old glycosaminoglycan</article-title><source>Glycobiol. Glycobiol.</source><year>2002</year><volume>12</volume><fpage>117R</fpage><lpage>1125R</lpage><pub-id pub-id-type="doi">10.1093/glycob/cwf066</pub-id></element-citation><mixed-citation id="mc-CR25" publication-type="journal">Trowbridge, J. M. Dermatan sulfate new functions from an old glycosaminoglycan. <italic>Glycobiol. Glycobiol.</italic><bold>12</bold>, 117R&#x02013;1125R (2002).</mixed-citation></citation-alternatives></ref><ref id="CR26"><label>26.</label><citation-alternatives><element-citation id="ec-CR26" publication-type="journal"><person-group person-group-type="author"><name><surname>Cortes-Medina</surname><given-names>M</given-names></name><etal/></person-group><article-title>Chondroitin sulfate, dermatan sulfate, and hyaluronic acid differentially modify the biophysical properties of collagen-based hydrogels</article-title><source>Acta Biomater.</source><year>2024</year><volume>174</volume><fpage>116</fpage><lpage>126</lpage><pub-id pub-id-type="doi">10.1016/j.actbio.2023.12.018</pub-id><pub-id pub-id-type="pmid">38101556</pub-id>
</element-citation><mixed-citation id="mc-CR26" publication-type="journal">Cortes-Medina, M. et al. Chondroitin sulfate, dermatan sulfate, and hyaluronic acid differentially modify the biophysical properties of collagen-based hydrogels. <italic>Acta Biomater.</italic><bold>174</bold>, 116&#x02013;126 (2024).<pub-id pub-id-type="pmid">38101556</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR27"><label>27.</label><citation-alternatives><element-citation id="ec-CR27" publication-type="journal"><person-group person-group-type="author"><name><surname>Gatto</surname><given-names>F</given-names></name><etal/></person-group><article-title>Plasma glycosaminoglycans as diagnostic and prognostic biomarkers in surgically treated renal cell carcinoma</article-title><source>Eur. Urol. Oncol.</source><year>2018</year><volume>1</volume><fpage>364</fpage><lpage>377</lpage><pub-id pub-id-type="doi">10.1016/j.euo.2018.04.015</pub-id><pub-id pub-id-type="pmid">31158075</pub-id>
</element-citation><mixed-citation id="mc-CR27" publication-type="journal">Gatto, F. et al. Plasma glycosaminoglycans as diagnostic and prognostic biomarkers in surgically treated renal cell carcinoma. <italic>Eur. Urol. Oncol.</italic><bold>1</bold>, 364&#x02013;377 (2018).<pub-id pub-id-type="pmid">31158075</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR28"><label>28.</label><citation-alternatives><element-citation id="ec-CR28" publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>S</given-names></name><name><surname>Li</surname><given-names>N</given-names></name><name><surname>Li</surname><given-names>L</given-names></name><name><surname>Zhan</surname><given-names>J</given-names></name></person-group><article-title>Sex difference in the association between serum versican and albuminuria in patients with type 2 diabetes mellitus</article-title><source>Diabetes Metabolic Syndrome Obes.</source><year>2023</year><volume>16</volume><fpage>3631</fpage><lpage>3639</lpage><pub-id pub-id-type="doi">10.2147/DMSO.S434287</pub-id></element-citation><mixed-citation id="mc-CR28" publication-type="journal">Li, S., Li, N., Li, L. &#x00026; Zhan, J. Sex difference in the association between serum versican and albuminuria in patients with type 2 diabetes mellitus. <italic>Diabetes Metabolic Syndrome Obes.</italic><bold>16</bold>, 3631&#x02013;3639 (2023).</mixed-citation></citation-alternatives></ref><ref id="CR29"><label>29.</label><citation-alternatives><element-citation id="ec-CR29" publication-type="journal"><person-group person-group-type="author"><name><surname>Fahlgren</surname><given-names>A</given-names></name><etal/></person-group><article-title>Interferon-&#x003b3; tempers the expression of carcinoembryonic antigen family molecules in human Colon cells: a possible role in innate mucosal defence</article-title><source>Scand. J. Immunol.</source><year>2003</year><volume>58</volume><fpage>628</fpage><lpage>641</lpage><pub-id pub-id-type="doi">10.1111/j.1365-3083.2003.01342.x</pub-id><pub-id pub-id-type="pmid">14636419</pub-id>
</element-citation><mixed-citation id="mc-CR29" publication-type="journal">Fahlgren, A. et al. Interferon-&#x003b3; tempers the expression of carcinoembryonic antigen family molecules in human Colon cells: a possible role in innate mucosal defence. <italic>Scand. J. Immunol.</italic><bold>58</bold>, 628&#x02013;641 (2003).<pub-id pub-id-type="pmid">14636419</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR30"><label>30.</label><citation-alternatives><element-citation id="ec-CR30" publication-type="journal"><person-group person-group-type="author"><name><surname>Brooks</surname><given-names>B</given-names></name><name><surname>Briggs</surname><given-names>DM</given-names></name><name><surname>Eastmond</surname><given-names>NC</given-names></name><name><surname>Fernig</surname><given-names>DG</given-names></name><name><surname>Coleman</surname><given-names>JW</given-names></name></person-group><article-title>Presentation of IFN-&#x003b3; to nitric Oxide-Producing cells: a novel function for mast cells</article-title><source>J. Immunol.</source><year>2000</year><volume>164</volume><fpage>573</fpage><lpage>579</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.164.2.573</pub-id><pub-id pub-id-type="pmid">10623797</pub-id>
</element-citation><mixed-citation id="mc-CR30" publication-type="journal">Brooks, B., Briggs, D. M., Eastmond, N. C., Fernig, D. G. &#x00026; Coleman, J. W. Presentation of IFN-&#x003b3; to nitric Oxide-Producing cells: a novel function for mast cells. <italic>J. Immunol.</italic><bold>164</bold>, 573&#x02013;579 (2000).<pub-id pub-id-type="pmid">10623797</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR31"><label>31.</label><citation-alternatives><element-citation id="ec-CR31" publication-type="journal"><person-group person-group-type="author"><name><surname>Lortat-Jacob</surname><given-names>H</given-names></name><name><surname>Baltzer</surname><given-names>F</given-names></name><name><surname>Grimaud</surname><given-names>JA</given-names></name></person-group><article-title>Heparin decreases the blood clearance of Interferon-&#x003b3; and increases its activity by limiting the processing of its Carboxyl-terminal sequence</article-title><source>J. Biol. Chem.</source><year>1996</year><volume>271</volume><fpage>16139</fpage><lpage>16143</lpage><pub-id pub-id-type="doi">10.1074/jbc.271.27.16139</pub-id><pub-id pub-id-type="pmid">8663206</pub-id>
</element-citation><mixed-citation id="mc-CR31" publication-type="journal">Lortat-Jacob, H., Baltzer, F. &#x00026; Grimaud, J. A. Heparin decreases the blood clearance of Interferon-&#x003b3; and increases its activity by limiting the processing of its Carboxyl-terminal sequence. <italic>J. Biol. Chem.</italic><bold>271</bold>, 16139&#x02013;16143 (1996).<pub-id pub-id-type="pmid">8663206</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR32"><label>32.</label><citation-alternatives><element-citation id="ec-CR32" publication-type="journal"><person-group person-group-type="author"><name><surname>Schmidt</surname><given-names>EP</given-names></name><etal/></person-group><article-title>The pulmonary endothelial glycocalyx regulates neutrophil adhesion and lung injury during experimental sepsis</article-title><source>Nat. Med.</source><year>2012</year><volume>18</volume><fpage>1217</fpage><lpage>1223</lpage><pub-id pub-id-type="doi">10.1038/nm.2843</pub-id><pub-id pub-id-type="pmid">22820644</pub-id>
</element-citation><mixed-citation id="mc-CR32" publication-type="journal">Schmidt, E. P. et al. The pulmonary endothelial glycocalyx regulates neutrophil adhesion and lung injury during experimental sepsis. <italic>Nat. Med.</italic><bold>18</bold>, 1217&#x02013;1223 (2012).<pub-id pub-id-type="pmid">22820644</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR33"><label>33.</label><citation-alternatives><element-citation id="ec-CR33" publication-type="journal"><person-group person-group-type="author"><name><surname>Nieuwdorp</surname><given-names>M</given-names></name><etal/></person-group><article-title>Tumor necrosis factor-&#x003b1; Inhibition protects against endotoxin-induced endothelial glycocalyx perturbation</article-title><source>Atherosclerosis</source><year>2009</year><volume>202</volume><fpage>296</fpage><lpage>303</lpage><pub-id pub-id-type="doi">10.1016/j.atherosclerosis.2008.03.024</pub-id><pub-id pub-id-type="pmid">18550063</pub-id>
</element-citation><mixed-citation id="mc-CR33" publication-type="journal">Nieuwdorp, M. et al. Tumor necrosis factor-&#x003b1; Inhibition protects against endotoxin-induced endothelial glycocalyx perturbation. <italic>Atherosclerosis</italic><bold>202</bold>, 296&#x02013;303 (2009).<pub-id pub-id-type="pmid">18550063</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR34"><label>34.</label><mixed-citation publication-type="other">Weber, M. &#x00026; Sixt, M. Interstitial dendritic cell guidance by Haptotactic chemokine gradients. <italic>Science</italic><bold>339</bold>, 328&#x02013;332 (2013).</mixed-citation></ref><ref id="CR35"><label>35.</label><citation-alternatives><element-citation id="ec-CR35" publication-type="journal"><person-group person-group-type="author"><name><surname>Frevert</surname><given-names>CW</given-names></name><etal/></person-group><article-title>Binding of Interleukin-8 to Heparan sulfate and chondroitin sulfate in lung tissue</article-title><source>Am. J. Respir. Cell Mol. Biol.</source><year>2003</year><volume>28</volume><fpage>464</fpage><lpage>472</lpage><pub-id pub-id-type="doi">10.1165/rcmb.2002-0084OC</pub-id><pub-id pub-id-type="pmid">12654635</pub-id>
</element-citation><mixed-citation id="mc-CR35" publication-type="journal">Frevert, C. W. et al. Binding of Interleukin-8 to Heparan sulfate and chondroitin sulfate in lung tissue. <italic>Am. J. Respir. Cell Mol. Biol.</italic><bold>28</bold>, 464&#x02013;472 (2003).<pub-id pub-id-type="pmid">12654635</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR36"><label>36.</label><citation-alternatives><element-citation id="ec-CR36" publication-type="journal"><person-group person-group-type="author"><name><surname>Lukasz</surname><given-names>A</given-names></name><etal/></person-group><article-title>Endothelial glycocalyx breakdown is mediated by angiopoietin-2</article-title><source>Cardiovasc. Res.</source><year>2017</year><volume>113</volume><fpage>671</fpage><lpage>680</lpage><pub-id pub-id-type="doi">10.1093/cvr/cvx023</pub-id><pub-id pub-id-type="pmid">28453727</pub-id>
</element-citation><mixed-citation id="mc-CR36" publication-type="journal">Lukasz, A. et al. Endothelial glycocalyx breakdown is mediated by angiopoietin-2. <italic>Cardiovasc. Res.</italic><bold>113</bold>, 671&#x02013;680 (2017).<pub-id pub-id-type="pmid">28453727</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR37"><label>37.</label><mixed-citation publication-type="other">Bush, M. A. et al. Degradation of endothelial glycocalyx in Tanzanian children with falciparum malaria. <italic>FASEB J.</italic><bold>35</bold>, 56 (2021).</mixed-citation></ref><ref id="CR38"><label>38.</label><citation-alternatives><element-citation id="ec-CR38" publication-type="journal"><person-group person-group-type="author"><name><surname>Mizumoto</surname><given-names>S</given-names></name><name><surname>Sugahara</surname><given-names>K</given-names></name></person-group><article-title>Glycosaminoglycans are functional ligands for receptor for advanced glycation end-products in tumors</article-title><source>FEBS J.</source><year>2013</year><volume>280</volume><fpage>2462</fpage><lpage>2470</lpage><pub-id pub-id-type="doi">10.1111/febs.12156</pub-id><pub-id pub-id-type="pmid">23360476</pub-id>
</element-citation><mixed-citation id="mc-CR38" publication-type="journal">Mizumoto, S. &#x00026; Sugahara, K. Glycosaminoglycans are functional ligands for receptor for advanced glycation end-products in tumors. <italic>FEBS J.</italic><bold>280</bold>, 2462&#x02013;2470 (2013).<pub-id pub-id-type="pmid">23360476</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR39"><label>39.</label><citation-alternatives><element-citation id="ec-CR39" publication-type="journal"><person-group person-group-type="author"><name><surname>Kol&#x000e1;&#x00159;ov&#x000e1;</surname><given-names>H</given-names></name><name><surname>Ambr&#x0016f;zov&#x000e1;</surname><given-names>B</given-names></name><name><surname>&#x00160;vih&#x000e1;lkov&#x000e1; &#x00160;indlerov&#x000e1;</surname><given-names>L</given-names></name><name><surname>Klinke</surname><given-names>A</given-names></name><name><surname>Kubala</surname><given-names>L</given-names></name></person-group><article-title>Modulation of endothelial glycocalyx structure under inflammatory conditions</article-title><source>Mediat. Inflamm.</source><year>2014</year><volume>2014</volume><fpage>1</fpage><lpage>17</lpage><pub-id pub-id-type="doi">10.1155/2014/694312</pub-id></element-citation><mixed-citation id="mc-CR39" publication-type="journal">Kol&#x000e1;&#x00159;ov&#x000e1;, H., Ambr&#x0016f;zov&#x000e1;, B., &#x00160;vih&#x000e1;lkov&#x000e1; &#x00160;indlerov&#x000e1;, L., Klinke, A. &#x00026; Kubala, L. Modulation of endothelial glycocalyx structure under inflammatory conditions. <italic>Mediat. Inflamm.</italic><bold>2014</bold>, 1&#x02013;17 (2014).</mixed-citation></citation-alternatives></ref><ref id="CR40"><label>40.</label><citation-alternatives><element-citation id="ec-CR40" publication-type="journal"><person-group person-group-type="author"><name><surname>Fdil</surname><given-names>N</given-names></name></person-group><article-title>Urinary glycosaminoglycans: characterization and quantification</article-title><source>Methods Mol. Biol.</source><year>2023</year><volume>2619</volume><fpage>61</fpage><lpage>69</lpage><pub-id pub-id-type="doi">10.1007/978-1-0716-2946-8_5</pub-id><pub-id pub-id-type="pmid">36662462</pub-id>
</element-citation><mixed-citation id="mc-CR40" publication-type="journal">Fdil, N. Urinary glycosaminoglycans: characterization and quantification. <italic>Methods Mol. Biol.</italic><bold>2619</bold>, 61&#x02013;69 (2023).<pub-id pub-id-type="pmid">36662462</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR41"><label>41.</label><citation-alternatives><element-citation id="ec-CR41" publication-type="journal"><person-group person-group-type="author"><name><surname>Kakkis</surname><given-names>E</given-names></name><name><surname>Marsden</surname><given-names>D</given-names></name></person-group><article-title>Urinary glycosaminoglycans as a potential biomarker for evaluating treatment efficacy in subjects with mucopolysaccharidoses</article-title><source>Mol. Genet. Metab.</source><year>2020</year><volume>130</volume><fpage>7</fpage><lpage>15</lpage><pub-id pub-id-type="doi">10.1016/j.ymgme.2020.02.006</pub-id><pub-id pub-id-type="pmid">32224020</pub-id>
</element-citation><mixed-citation id="mc-CR41" publication-type="journal">Kakkis, E. &#x00026; Marsden, D. Urinary glycosaminoglycans as a potential biomarker for evaluating treatment efficacy in subjects with mucopolysaccharidoses. <italic>Mol. Genet. Metab.</italic><bold>130</bold>, 7&#x02013;15 (2020).<pub-id pub-id-type="pmid">32224020</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR42"><label>42.</label><citation-alternatives><element-citation id="ec-CR42" publication-type="journal"><person-group person-group-type="author"><name><surname>Evans</surname><given-names>L</given-names></name><etal/></person-group><article-title>Surviving Sepsis campaign: international guidelines for management of Sepsis and septic shock 2021</article-title><source>Crit. Care Med.</source><year>2021</year><volume>49</volume><fpage>e1063</fpage><lpage>e1143</lpage><pub-id pub-id-type="doi">10.1097/CCM.0000000000005337</pub-id><pub-id pub-id-type="pmid">34605781</pub-id>
</element-citation><mixed-citation id="mc-CR42" publication-type="journal">Evans, L. et al. Surviving Sepsis campaign: international guidelines for management of Sepsis and septic shock 2021. <italic>Crit. Care Med.</italic><bold>49</bold>, e1063&#x02013;e1143 (2021).<pub-id pub-id-type="pmid">34605781</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR43"><label>43.</label><citation-alternatives><element-citation id="ec-CR43" publication-type="journal"><person-group person-group-type="author"><name><surname>Broekhuizen</surname><given-names>LN</given-names></name><etal/></person-group><article-title>Effect of sulodexide on endothelial glycocalyx and vascular permeability in patients with type 2 diabetes mellitus</article-title><source>Diabetologia</source><year>2010</year><volume>53</volume><fpage>2646</fpage><lpage>2655</lpage><pub-id pub-id-type="doi">10.1007/s00125-010-1910-x</pub-id><pub-id pub-id-type="pmid">20865240</pub-id>
</element-citation><mixed-citation id="mc-CR43" publication-type="journal">Broekhuizen, L. N. et al. Effect of sulodexide on endothelial glycocalyx and vascular permeability in patients with type 2 diabetes mellitus. <italic>Diabetologia</italic><bold>53</bold>, 2646&#x02013;2655 (2010).<pub-id pub-id-type="pmid">20865240</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR44"><label>44.</label><citation-alternatives><element-citation id="ec-CR44" publication-type="journal"><person-group person-group-type="author"><name><surname>Chappell</surname><given-names>D</given-names></name><etal/></person-group><article-title>Hypervolemia increases release of atrial natriuretic peptide and shedding of the endothelial glycocalyx</article-title><source>Crit. Care</source><year>2014</year><volume>18</volume><fpage>538</fpage><pub-id pub-id-type="doi">10.1186/s13054-014-0538-5</pub-id><pub-id pub-id-type="pmid">25497357</pub-id>
</element-citation><mixed-citation id="mc-CR44" publication-type="journal">Chappell, D. et al. Hypervolemia increases release of atrial natriuretic peptide and shedding of the endothelial glycocalyx. <italic>Crit. Care</italic><bold>18</bold>, 538 (2014).<pub-id pub-id-type="pmid">25497357</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR45"><label>45.</label><citation-alternatives><element-citation id="ec-CR45" publication-type="journal"><person-group person-group-type="author"><name><surname>Dixon</surname><given-names>B</given-names></name><etal/></person-group><article-title>Nebulised heparin for patients with or at risk of acute respiratory distress syndrome: a multicentre, randomised, double-blind, placebo-controlled phase 3 trial</article-title><source>Lancet Respir. Med.</source><year>2021</year><volume>9</volume><fpage>360</fpage><lpage>372</lpage><pub-id pub-id-type="doi">10.1016/S2213-2600(20)30470-7</pub-id><pub-id pub-id-type="pmid">33493448</pub-id>
</element-citation><mixed-citation id="mc-CR45" publication-type="journal">Dixon, B. et al. Nebulised heparin for patients with or at risk of acute respiratory distress syndrome: a multicentre, randomised, double-blind, placebo-controlled phase 3 trial. <italic>Lancet Respir. Med.</italic><bold>9</bold>, 360&#x02013;372 (2021).<pub-id pub-id-type="pmid">33493448</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR46"><label>46.</label><citation-alternatives><element-citation id="ec-CR46" publication-type="journal"><person-group person-group-type="author"><name><surname>Lever</surname><given-names>R</given-names></name><name><surname>Rose</surname><given-names>MJ</given-names></name><name><surname>McKenzie</surname><given-names>EA</given-names></name><name><surname>Page</surname><given-names>CP</given-names></name></person-group><article-title>Heparanase induces inflammatory cell recruitment in vivo by promoting adhesion to vascular endothelium</article-title><source>Am. J. Physiol.-Cell Physiol.</source><year>2014</year><volume>306</volume><fpage>C1184</fpage><lpage>C1190</lpage><pub-id pub-id-type="doi">10.1152/ajpcell.00269.2013</pub-id><pub-id pub-id-type="pmid">24740543</pub-id>
</element-citation><mixed-citation id="mc-CR46" publication-type="journal">Lever, R., Rose, M. J., McKenzie, E. A. &#x00026; Page, C. P. Heparanase induces inflammatory cell recruitment in vivo by promoting adhesion to vascular endothelium. <italic>Am. J. Physiol.-Cell Physiol.</italic><bold>306</bold>, C1184&#x02013;C1190 (2014).<pub-id pub-id-type="pmid">24740543</pub-id>
</mixed-citation></citation-alternatives></ref></ref-list></back></article>